Endra Life Sciences INC 8-K filings
NASDAQ
ENDRA Life Sciences has successfully priced a public offering, raising approximately $8 million to support working capital and general corporate purposes.
NASDAQ
8-K: ENDRA Life Sciences Gains Clarity on Regulatory Path for TAEUS Liver Device Following FDA Meeting
ENDRA Life Sciences reports a productive pre-submission meeting with the FDA regarding its TAEUS liver device, clarifying the regulatory path forward.
NASDAQ
ENDRA Life Sciences announced its first quarter 2024 financial results, highlighted by the first UK installation of its TAEUS system and progress with FDA regulatory alignment.
NASDAQ
ENDRA Life Sciences reported preliminary unaudited financial results for Q1 2024, including a net loss of approximately $2.8 million and no revenue, while also announcing a public offering of common stock and warrants.
NASDAQ
ENDRA Life Sciences has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, placing its listing at risk.
NASDAQ
ENDRA Life Sciences announced its 2023 financial results, highlighting reduced operating expenses and net losses, along with progress in the clinical evaluation and regulatory process for its TAEUS system.